Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D1.481 - Prevalence of Immunoglobulin Deficiency in Patients with Chronic Rhinosinusitis Followed in a Tertiary Referral Center
D1.487 - Evaluation of Large Language Models in Otolaryngology: Accuracy on Structured Question Banks and S.C.O.R.E.-Based Interpretation of Guidelines and Consensus Statements
D1.485 - Characterization of CRSwNP and associated Type 2 or Respiratory comorbidities in the biological era in Spain - The POLARIS study
D1.490 - Dupilumab in the treatment of Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Cystic Fibrosis patients
D1.492 - Efficacy and safety of a combined nasal spray with a fixed dose of mometasone and olopatadine for the treatment of allergic rhinitis in pets under save ongoing exposure to epidermal allergens
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.461 - Endothelial related miRs are dysregulated in C1-INH Angioedema patients: new potential biomarkers and therapeutic targets
D2.462 - Safety and predictors of tolerance in rituximab hypersensitivity management
D3.17 - Outcomes of Anti-Tuberculosis Drug Reintroduction Following Adverse Drug Reactions among Adult Patients at a Tertiary Hospital in the Philippines (2022-2024)
D3.30 - Automated generation of structured clinical databases in drug hypersensitivity: real-world validation in patients with proton pump inhibitor reactions
D3.18 - Role of an Allergological Work-up in Antibiotic Allergy Delabeling in Mexican Pediatric Patients
D3.20 - Study of “in vitro” cross reactivity between nsLTP’s comparing “in silico” results with a new specific IgE test based on immunoblot methodology
D3.21 - When the Patient Diagnoses Herself: Amoxicillin-Induced Acute Pancreatitis as a Rare Manifestation of Drug Hypersensitivity
D3.31 - Real-world Practices in the Diagnosis and Evaluation of Allergic Rhinitis among Korean Specialists
D3.28 - Effectiveness of the Hypoallergenic Home Visit Program in Treating Moderate-to-Severe Allergic Rhinitis: An Environmental Control Study in Southern China
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download